Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:59 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of Mitapivat in Participants With Sickle Cell Disease and Nephropathy
NCT06286046 · Agios Pharmaceuticals, Inc. · PHASE2 · withdrawn · last registry update 2026-04-03 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Withdrawn prior to study start per sponsor decision. No patients were enrolled.” | – | Registry record, Agios Pharmaceuticals, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PKLR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-09-03Also stopped (terminated): Forma Therapeutics, Inc., Etavopivat (NCT05568225)
- 2026-06-18Phase 3 first posted: Agios Pharmaceuticals, Inc., Mitapivat Matched Placebo + Mitapivat (NCT07656415)
- 2026-04-08Phase 3 first posted: Agios Pharmaceuticals, Inc., Mitapivat + Placebo Matching Mitapivat (NCT07517133)
- 2026-04-02Phase 3 first posted: Agios Pharmaceuticals, Inc., Mitapivat Matched Placebo + Mitapivat (NCT07506863)
- 2025-11-18Results posted on the registry: Agios Pharmaceuticals, Inc., Mitapivat (NCT03853798)
- 2025-10-22Results posted on the registry: Forma Therapeutics, Inc., Etavopivat (NCT05568225)
- 2025-05-25Results posted on the registry: Agios Pharmaceuticals, Inc., Placebo Matching Mitapivat + Mitapivat (NCT04770779)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision